Tatjana Adžić-Vukičević

1PUBLICATIONS
11CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

Sort by Publication Date:
|Sep 27, 2025
Real World Data on the Efficacy of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer: A Single-Center Experience.

Vesna Ćeriman Krstić, Natalija Samardžić, Mihailo Stjepanović

Pageof 1

Frequent Collaborators

1 joint publications

Vesna Ćeriman Krstić

1 joint publications

Mihailo Stjepanović

1 joint publications

Spasoje Popević

1 joint publications

Sofija Glumac

1 joint publications

Ruža Stević

1 joint publications

Dragana Marić

1 joint publications

Milena Jovanović

1 joint publications

Branislav Ilić

1 joint publications

Nikola Čolić

1 joint publications

Ivana Sekulović Radovanović

Frequent Collaborators

1 joint publications

Vesna Ćeriman Krstić

1 joint publications

Mihailo Stjepanović

1 joint publications

Spasoje Popević

1 joint publications

Sofija Glumac

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.4K
See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.4K
See more related videos